Research and laboratory use only. Not for human consumption.
GHRP-6
GHRP-6 is a synthetic six-amino-acid growth hormone secretagogue developed before the discovery of ghrelin. It activates the growth hormone secretagogue receptor, now known as the ghrelin receptor, and has been studied extensively in humans for its ability to stimulate pulsatile growth hormone secretion.
What is GHRP-6?
GHRP-6 is a synthetic hexapeptide developed as part of a family of compounds known as growth hormone-releasing peptides, or GHRPs.
Its sequence is: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 . Unlike ordinary naturally occurring peptides, the sequence contains D-amino acids, which were introduced during medicinal-chemistry development to improve biological activity and resistance to enzymatic breakdown.
GHRP-6 stimulates release of growth hormone from the pituitary and also acts through hypothalamic mechanisms.
It does not bind the conventional growth hormone-releasing hormone receptor. Instead it activates a separate receptor that became known as the growth hormone secretagogue receptor.
Several years after GHRP-6 had already been studied in humans, the natural ligand for that receptor was discovered and named ghrelin.
Why is it called GHRP-6?
GHRP stands for Growth Hormone-Releasing Peptide, describing the effect that led to the compound's development.
The number 6 reflects its identity as a six-residue peptide.
The two residues written as D-Trp and D-Phe use the D-stereochemical form of those amino acids.
This is a major difference from natural human peptide hormones, which are built almost entirely from L-amino acids. GHRP-6 is therefore best described as a synthetic peptidomimetic secretagogue, rather than a naturally occurring human hormone.
Synthetic peptides helped reveal a new hormone system
GHRP research preceded discovery of both the growth hormone secretagogue receptor and its natural ligand, ghrelin.
Why was GHRP-6 important scientifically?
The history of GHRP-6 is unusual because researchers discovered the synthetic pharmacology before they understood the natural physiological system.
Early peptide work beginning in the 1970s produced synthetic compounds capable of releasing growth hormone despite having no structural similarity to natural GHRH.
GHRP-6 became the first member of this family to demonstrate strong in-vivo GH-releasing activity.
The fact that GHRP-6 acted through a pathway different from GHRH suggested the existence of another receptor and perhaps another natural hormone controlling GH secretion.
That receptor was cloned in 1996. In 1999, researchers identified the stomach-derived hormone ghrelin as its endogenous ligand.
Amino-acid sequence
GHRP-6 contains six residues, including two deliberately incorporated D-amino acids and an amidated C-terminus.
Why are researchers interested in GHRP-6?
GHRP-6 became a useful experimental tool for studying growth-hormone physiology because it stimulates the GH axis through a pathway distinct from GHRH.
GH Secretion
Human studies consistently demonstrate acute stimulation of growth-hormone secretion following GHRP-6 exposure.
Hypothalamic Regulation
GHRP-6 helped researchers understand how hypothalamic GHRH and somatostatin interact with the secretagogue pathway.
GH Diagnostic Testing
GHRH plus GHRP-6 has been investigated as a provocative test of pituitary GH reserve in adults with suspected growth-hormone deficiency.
Appetite & Metabolism
GHRP research helped reveal that the ghrelin receptor regulates not only GH secretion but also feeding and metabolic biology.
How does GHRP-6 stimulate growth hormone?
GHRP-6 activates the ghrelin receptor at both pituitary and hypothalamic levels. Its interaction with endogenous GHRH and somatostatin makes the resulting physiology more complex than direct pituitary stimulation alone.
GHS-R1a Activation
GHRP-6 is an agonist of the growth hormone secretagogue receptor, now officially referred to as the ghrelin receptor.
Hypothalamic Effects
The compound interacts with central regulatory pathways controlling endogenous growth-hormone pulses.
Pituitary Somatotrophs
GHRP-6 can directly stimulate growth-hormone-producing pituitary cells, although human responses depend strongly on intact hypothalamic signalling.
GHRH Synergy
Simultaneous GHRH and GHRP-6 produces a GH response substantially greater than either secretagogue alone in many human studies.
GHRP-6 and GHRH are complementary signals
GHRP-6 is sometimes described simply as a direct pituitary GH releaser, but human experiments show that this is incomplete.
In healthy volunteers, blockade of the endogenous GHRH system removed most of the growth-hormone response to GHRP-6.
Conversely, administering GHRH and GHRP-6 together can produce a much greater GH response than either compound alone.
This synergy made the combination useful experimentally as a test of pituitary GH reserve and helped reveal the physiological interaction between the ghrelin and GHRH systems.
What potential human applications were investigated?
GHRP-6 has been administered in human research, but this does not make it an established medicine. The areas below describe scientific and historical development interests.
Growth Hormone Deficiency Testing
GHRH plus GHRP-6 was extensively studied as a provocative diagnostic test capable of distinguishing normal GH reserve from severe pituitary growth-hormone deficiency.
GH Secretory Disorders
Researchers used GHRP-6 to investigate growth-hormone secretion in obesity, diabetes, acromegaly, Cushing's syndrome and other endocrine states.
Appetite & Wasting Research
Discovery of the ghrelin receptor's role in appetite led to broader investigation of ghrelin-receptor agonists for appetite loss and cachexia. Later compounds, rather than GHRP-6 itself, became the main focus of clinical development.
Ghrelin-Receptor Drug Development
GHRP-6 provided an important pharmacological starting point for newer peptide and non-peptide GHS-R1a agonists with improved potency, selectivity and pharmacokinetic properties.
GHRP-6 has demonstrated pharmacological activity in human experiments, particularly acute GH release, but this does not establish long-term safety, therapeutic benefit or an approved indication.
How strong is the evidence?
GHRP-6 has much stronger direct human pharmacodynamic evidence than many research peptides, but evidence for therapeutic benefit is considerably less developed.
Molecular Evidence
GHS-R1a binding and receptor-mediated signalling are well established.
Human Pharmacology
Numerous controlled human experiments demonstrate acute stimulation of GH secretion.
Diagnostic Research
GHRH/GHRP-6 testing has been evaluated in large cohorts for assessment of adult GH deficiency.
Established Therapy
Long-term clinical efficacy and an approved therapeutic indication for GHRP-6 itself have not been established.
What do we know from human studies?
Direct human pharmacology is established, but long-term therapeutic evidence is not.
Unlike many modern research peptides, GHRP-6 has been directly administered to substantial numbers of human participants in endocrine research.
Studies in healthy adults consistently demonstrated marked acute GH release. Similar experiments examined responses in obesity, growth-hormone deficiency, diabetes, acromegaly and Cushing's syndrome.
One diagnostic investigation evaluated 125 adults with organic pituitary disease and 125 healthy controls using combined GHRH and GHRP-6. The resulting GH response distinguished severe GH deficiency from normal pituitary reserve in that study.
Human experiments also established that GHRP-6 works synergistically with GHRH. In some studies, the combined GH response was substantially greater than the arithmetic sum of responses to either compound alone.
These findings establish acute endocrine pharmacology. They do not establish that chronic GHRP-6 administration improves body composition, muscle growth, recovery, longevity or other outcomes commonly claimed outside the clinical literature.
Where is GHRP-6 in the development process?
GHRP-6 became an important experimental and diagnostic research molecule, but pharmaceutical development largely moved toward newer secretagogues with better selectivity and pharmacokinetic properties.
Human-studied research secretagogue
GHRP-6 has a strong record as a human endocrine research tool, but newer ghrelin-receptor agonists and other secretagogues became more attractive for pharmaceutical development.
What don't we know?
Factors affecting peptide stability
GHRP-6 contains D-amino acids and a C-terminal amide, structural modifications that distinguish it from ordinary endogenous peptide hormones. Stability should nevertheless be evaluated using compound-specific analytical documentation.
Temperature
Temperature can influence peptide degradation and long-term chemical stability.
Moisture
Moisture can alter physical and chemical characteristics of peptide material.
Solution Conditions
pH, buffer, concentration and solvent can affect peptide stability in experimental solutions.
Peptide Form
Salt form, purity and analytical identity should be specified for the exact laboratory material under study.
Human-studied investigational secretagogue — not an approved general therapeutic medicine
GHRP-6 has been administered to humans in numerous controlled endocrine studies and its acute ability to stimulate growth hormone is well documented.
This human pharmacology should not be confused with therapeutic approval. Long-term clinical efficacy and safety for uses such as muscle growth, recovery, body-composition alteration, anti-ageing or appetite modification have not been established for GHRP-6 as a general medicine.
ASA Research Labs provides this information for scientific and educational purposes only. Nothing on this page should be interpreted as medical advice, dosing guidance or a recommendation for human use.
Selected scientific references
The references below include foundational receptor research, human endocrine studies and reviews of the growth hormone secretagogue and ghrelin systems.
Scientific research information only
This profile is provided for scientific and educational information. GHRP-6 has been administered in controlled human endocrine studies, but it is not presented by ASA Research Labs as an approved treatment for growth-hormone deficiency, muscle growth, appetite disorders, recovery, body-composition change or any other medical condition. Discussion of acute hormone responses does not establish long-term safety or therapeutic efficacy. This page does not provide instructions for administration, dosing or human use.